• Je něco špatně v tomto záznamu ?

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238

J. Weber, M. Del Vecchio, M. Mandalá, H. Gogas, AM. Arance, S. Dalle, CL. Cowey, M. Schenker, JJ. Grob, V. Chiarion-Sileni, I. Márquez-Rodas, MO. Butler, AM. Di Giacomo, L. de la Cruz-Merino, P. Arenberger, V. Atkinson, A. Hill, LA. Fecher, M....

. 2024 ; 42 (31) : 3702-3712. [pub] 20240805

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, klinické zkoušky, fáze III

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003707

PURPOSE: In phase III CheckMate 238, adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with resected stage IIIB-C/IV melanoma without a significant difference in overall survival (OS). Here, we investigate progression-free survival (PFS) and OS after postrecurrence systemic therapy. PATIENTS AND METHODS: Patients 15 years or older with resected stage IIIB-C/IV melanoma were stratified by stage and tumor PD-L1 status and randomly assigned to receive nivolumab 3 mg/kg every 2 weeks, or ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks for 1 year or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Patients with recurrence in each group were assessed for PFS and OS from subsequent systemic therapy (SST) initiation per recurrence timing (≤12 months [early] v >12 months [late] from initial therapy). RESULTS: Recurrences occurred in 198 (44%) of 453 nivolumab-treated patients (122 early, 76 late) and 232 (51%) of 453 ipilimumab-treated patients (160 early, 72 late). Median PFS on next-line systemic therapy for nivolumab-treated patients recurring early versus late was 4.7 versus 12.4 months (24-month rates, 16% v 31%); median OS was 19.8 versus 42.8 months (24-month rates: 37% v 73%). In response to subsequent therapy, patients on nivolumab with late versus early recurrence were more likely to benefit from anti-PD-1 monotherapy. Nivolumab-treated patients with either an early or late recurrence benefitted from an ipilimumab-based therapy or targeted therapy, each with similar OS. CONCLUSION: Postrecurrence survival was longer for patients who recurred >12 months. Patients on nivolumab who recurred early benefitted from SST but had better survival with ipilimumab-based regimens or targeted therapy compared with anti-PD-1 monotherapy.

Center for Immuno Oncology University Hospital of Siena Siena University of Siena Italy

Department of Clinical Oncology Instituto de Biomedicina de Sevilla IBiS Hospital Universitario Virgen Macarena CSIC Universidad de Sevilla Hospital University Virgen Macarena Seville Spain

Department of Cutaneous Oncology H Lee Moffitt Cancer Center Tampa FL

Department of Dermatology Aix Marseille University Hôpital de la Timone Marseille France

Department of Dermatology Charles University 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Dermatology Hospices Civils de Lyon Pierre Bénite France

Department of Internal Medicine National and Kapodistrian University of Athens Athens Greece

Department of Internal Medicine University of Western Australia and Sir Charles Gairdner Hospital Nedlands WA Australia

Department of Medical Oncology and Hematology Department of Medicine Department of Immunology University of Toronto Princess Margaret Cancer Centre Toronto ON Canada

Department of Medical Oncology General University Hospital Gregorio Marañón and CIBERONC Madrid Spain

Department of Medical Oncology Hospital Clínic de Barcelona IDIBAPS Barcelona Spain

Department of Medical Oncology Tasman Health Care Southport QLD Australia

Department of Medical Oncology Texas Oncology Baylor Charles A Sammons Cancer Center Dallas TX

Department of Medical Oncology The Royal Marsden NHS Foundation Trust London United Kingdom

Division of Cancer Services Gallipoli Medical Research Foundation University of Queensland Brisbane QLD Australia

Division of Hematology Oncology Department of Internal Medicine University of Michigan Rogel Cancer Center Ann Arbor MI

Istituto Nazionale Tumori IRCCS Fondazione Pascale Naples Italy

Laura and Isaac Perlmutter Cancer Center NYU Langone Health New York NY

Medical Oncology of Melanoma Sarcoma and Rare Tumors IEO European Institute of Oncology IRCCS Milan Italy

Melanoma Institute Australia The University of Sydney and Royal North Shore and Mater Hospitals Sydney NSW Australia

Melanoma Oncology Unit Veneto Institute of Oncology IOV IRCCS Padua Italy

Oncology Center Sf Nectarie Craiova Romania

Oncology Clinical Development Bristol Myers Squibb Princeton NJ

Papa Giovanni XIII Hospital Bergamo Italy

Unit of Melanoma Medical Oncology Department of Medical Oncology and Hematology Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003707
003      
CZ-PrNML
005      
20250206104630.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.23.01448 $2 doi
035    __
$a (PubMed)39102624
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Weber, Jeffrey $u Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY $1 https://orcid.org/0000000249622957
245    10
$a Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238 / $c J. Weber, M. Del Vecchio, M. Mandalá, H. Gogas, AM. Arance, S. Dalle, CL. Cowey, M. Schenker, JJ. Grob, V. Chiarion-Sileni, I. Márquez-Rodas, MO. Butler, AM. Di Giacomo, L. de la Cruz-Merino, P. Arenberger, V. Atkinson, A. Hill, LA. Fecher, M. Millward, NI. Khushalani, P. Queirolo, GV. Long, M. Lobo, M. Askelson, PA. Ascierto, J. Larkin
520    9_
$a PURPOSE: In phase III CheckMate 238, adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with resected stage IIIB-C/IV melanoma without a significant difference in overall survival (OS). Here, we investigate progression-free survival (PFS) and OS after postrecurrence systemic therapy. PATIENTS AND METHODS: Patients 15 years or older with resected stage IIIB-C/IV melanoma were stratified by stage and tumor PD-L1 status and randomly assigned to receive nivolumab 3 mg/kg every 2 weeks, or ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks for 1 year or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Patients with recurrence in each group were assessed for PFS and OS from subsequent systemic therapy (SST) initiation per recurrence timing (≤12 months [early] v >12 months [late] from initial therapy). RESULTS: Recurrences occurred in 198 (44%) of 453 nivolumab-treated patients (122 early, 76 late) and 232 (51%) of 453 ipilimumab-treated patients (160 early, 72 late). Median PFS on next-line systemic therapy for nivolumab-treated patients recurring early versus late was 4.7 versus 12.4 months (24-month rates, 16% v 31%); median OS was 19.8 versus 42.8 months (24-month rates: 37% v 73%). In response to subsequent therapy, patients on nivolumab with late versus early recurrence were more likely to benefit from anti-PD-1 monotherapy. Nivolumab-treated patients with either an early or late recurrence benefitted from an ipilimumab-based therapy or targeted therapy, each with similar OS. CONCLUSION: Postrecurrence survival was longer for patients who recurred >12 months. Patients on nivolumab who recurred early benefitted from SST but had better survival with ipilimumab-based regimens or targeted therapy compared with anti-PD-1 monotherapy.
650    _2
$a lidé $7 D006801
650    12
$a melanom $x farmakoterapie $x mortalita $x patologie $7 D008545
650    12
$a inhibitory kontrolních bodů $x terapeutické užití $x škodlivé účinky $7 D000082082
650    12
$a nivolumab $x terapeutické užití $7 D000077594
650    12
$a ipilimumab $x terapeutické užití $x aplikace a dávkování $7 D000074324
650    12
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory kůže $x farmakoterapie $x patologie $x mortalita $7 D012878
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a staging nádorů $7 D009367
650    _2
$a doba přežití bez progrese choroby $7 D000077982
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
700    1_
$a Del Vecchio, Michele $u Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
700    1_
$a Mandalá, Mario $u Papa Giovanni XIII Hospital, Bergamo, Italy $1 https://orcid.org/0000000188468959
700    1_
$a Gogas, Helen $u Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece $1 https://orcid.org/0000000204512885
700    1_
$a Arance, Ana M $u Department of Medical Oncology, Hospital Clínic de Barcelona-IDIBAPS, Barcelona, Spain
700    1_
$a Dalle, Stephane $u Department of Dermatology, Hospices Civils de Lyon, Pierre Bénite, France
700    1_
$a Cowey, C Lance $u Department of Medical Oncology, Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX
700    1_
$a Schenker, Michael $u Oncology Center Sf Nectarie, Craiova, Romania $1 https://orcid.org/0000000326456391
700    1_
$a Grob, Jean-Jacques $u Department of Dermatology, Aix-Marseille University, Hôpital de la Timone, Marseille, France $1 https://orcid.org/000000020667153X
700    1_
$a Chiarion-Sileni, Vanna $u Melanoma Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy $1 https://orcid.org/0000000191919124
700    1_
$a Márquez-Rodas, Iván $u Department of Medical Oncology, General University Hospital Gregorio Marañón and CIBERONC, Madrid, Spain $1 https://orcid.org/000000022476668X
700    1_
$a Butler, Marcus O $u Department of Medical Oncology and Hematology, Department of Medicine, Department of Immunology University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada $1 https://orcid.org/0000000298407057
700    1_
$a Di Giacomo, Anna Maria $u Center for Immuno-Oncology, University Hospital of Siena, Siena, University of Siena, Italy
700    1_
$a de la Cruz-Merino, Luis $u 4Department of Clinical Oncology, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, Hospital University Virgen Macarena, Seville, Spain $1 https://orcid.org/0000000253330535
700    1_
$a Arenberger, Petr $u 5Department of Dermatology, Charles University Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic $1 https://orcid.org/0000000248005877 $7 nlk19990072992
700    1_
$a Atkinson, Victoria $u 6Division of Cancer Services, Gallipoli Medical Research Foundation, University of Queensland, Brisbane, QLD, Australia
700    1_
$a Hill, Andrew $u 7Department of Medical Oncology, Tasman Health Care, Southport, QLD, Australia
700    1_
$a Fecher, Leslie A $u 8Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, MI $1 https://orcid.org/0000000265347457
700    1_
$a Millward, Michael $u Department of Internal Medicine, University of Western Australia and Sir Charles Gairdner Hospital, Nedlands, WA, Australia $1 https://orcid.org/0000000217441617 $7 xx0113999
700    1_
$a Khushalani, Nikhil I $u 0Department of Cutaneous Oncology, H Lee Moffitt Cancer Center, Tampa, FL $1 https://orcid.org/0000000236364143
700    1_
$a Queirolo, Paola $u 1Medical Oncology of Melanoma, Sarcoma and Rare Tumors, IEO European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Long, Georgina V $u 2Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia $1 https://orcid.org/0000000188943545
700    1_
$a Lobo, Maurice $u 3Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ $1 https://orcid.org/0009000846746744
700    1_
$a Askelson, Margarita $u 3Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ
700    1_
$a Ascierto, Paolo A $u Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy $1 https://orcid.org/000000028322475X
700    1_
$a Larkin, James $u Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom $1 https://orcid.org/0000000155699523
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 42, č. 31 (2024), s. 3702-3712
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39102624 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104626 $b ABA008
999    __
$a ok $b bmc $g 2263461 $s 1239714
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 42 $c 31 $d 3702-3712 $e 20240805 $i 1527-7755 $m Journal of clinical oncology $n J Clin Oncol $x MED00002596
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace